Keyphrases
Entrapment
100%
Leptomycin B
100%
Myeloid Leukemia Cells
100%
CD34+
100%
Chronic Myeloid Leukemia
100%
Imatinib Mesylate
100%
BCR-ABL
100%
Novartis
66%
Switzerland
33%
Tyrosine Kinase
33%
Anti-apoptotic
33%
Apoptotic Pathway
33%
Chronic Myelogenous Leukemia Cells
33%
Princeton
33%
Second-generation TKI
33%
Kinase Domain mutations
33%
Tyrosine Kinase Inhibitor
33%
Fusion Oncoprotein
33%
Nilotinib
33%
Molecular Remission
33%
Dasatinib
33%
Tasigna
33%
Glivec
33%
Hematopoietic Stem Cells
33%
T315I mutation
33%
Resistance Mechanisms
33%
Constitutively Active
33%
Philadelphia Chromosome
33%
Complete Cytogenetic Response
33%
Biochemistry, Genetics and Molecular Biology
Myeloid
100%
CD34
100%
Imatinib
100%
Leptomycin
100%
Mesylate
100%
Dasatinib
66%
Signal Transduction
33%
Kinase
33%
Phosphotransferase
33%
Stem Cell
33%
Cytogenetics
33%
Receptor Tyrosine Kinase
33%
Nilotinib
33%
Philadelphia Chromosome
33%
Tyrosine Kinase Inhibitor
33%
Hematopoietic Stem Cell
33%
Tyrosine Kinase
33%
Medicine and Dentistry
Chronic Myelogenous Leukemia
100%
Leptomycin B
100%
Imatinib
100%
Leukemia Cell
100%
Dasatinib
66%
Nilotinib
66%
Signal Transduction
33%
Phosphotransferase
33%
Oncoprotein
33%
Protein Tyrosine Kinase
33%
Hematopoietic Stem Cell
33%
Tyrosine-Kinase Inhibitor
33%
Philadelphia 1 Chromosome
33%
Antiapoptotic
33%
Stem Cell
33%
Pharmacology, Toxicology and Pharmaceutical Science
Leptomycin B
100%
Imatinib
100%
Chronic Myeloid Leukemia
100%
Nilotinib
66%
Dasatinib
66%
Phosphotransferase
33%
Remission
33%
Protein Tyrosine Kinase
33%
Antiapoptotic
33%
Protein Tyrosine Kinase Inhibitor
33%
Philadelphia 1 Chromosome
33%
Oncoprotein
33%